Diabetes Mellitus, Type 2Phase 2/3NCT00821977
Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
A Phase 2/3 study testing Vildagliptin in people with Diabetes Mellitus, Type 2, run by Novartis at 176 sites in 8 countries.
Trial summary
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Vildagliptin
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 338 participants
- Where
- 176 sitesin 8 countries
- Study dates
- Nov 2008to Oct 2010
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients at least 18 years of age at Visit 1
- Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1
- HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1
- Body Mass Index (BMI) in the range of 22-45 kg/m2 at Visit 1
Who cannot join
- Pregnant or lactating female
- FPG ≥ 270 mg/dL (≥15 mmol/L)
- Other protocol-defined inclusion/exclusion criteria may apply
Trial locations and contacts
176 sites in 8 countries.
176 sites in 8 countries
United States141 sites
ACRC Trials
Addison, Texas, 75093
The Endocrine Group, LLP
Albany, New York, 12206
JMG CIinical Research
Alton, Illinois, 62002
Blair Medical Associates Inc
Altoona, Pennsylvania, 16602
Hartwell Research Group, LLC
Anderson, South Carolina, 29621
Sall Research Medical Center
Artesia, California, 90704
Southern Clinical Research
Augusta, Georgia, 30904
Fox Valley Clinical Research
Aurora, Illinois, 60504
AM Diabetes and Endocrinology Center
Bartlett, Tennessee, 38133
Dolby Research, LLC
Baton Rouge, Louisiana, 70809
Discover Research Inc.
Beaumont, Texas, 77701
MW Clinical Research
Beaumont, Texas, 77701
Tri-State Medical Group
Beaver, Pennsylvania, 15009
Madrona Medical Group - Clinical Research Dept.
Bellingham, Washington, 98226
Belzoni Clinical Research
Belzoni, Mississippi, 39038
Progressive Clinical Research
Bountiful, Utah, 84010
Tri-Cities Medical Research
Bristol, Tennessee, 37620
Discover Research
Bryan, Texas, 77802
Associated Pharmaceutical Research
Buena Park, California, 90620
Providence Research
Burbank, California, 91505
Burbank - Lovelace Scientific Resources, Inc.
Burbank, California, 91506
Cornerstone Medical Center
Burlington, North Carolina, 27215
Kernodle Clinic, Inc.
Burlington, North Carolina, 27215
Low Country Internal Medicine
Charleston, South Carolina, 29406
Pharmacorp Clinical Trials, INC
Charleston, South Carolina, 29412
Neem Research Group of Charlotte
Charlotte, North Carolina, 28262
Michigan Hypertension Center
Chelsea, Michigan, 48118
Woodlake Research
Chesterfield, Missouri, 63017
Midwest Pharmaceutical Research Inc.
City of Saint Peters, Missouri, 63376
Midwest Pharmaceutical Research, Inc.
City of Saint Peters, Missouri, 63376
The Family Healthcare Center
Clinton, South Carolina, 29325
Colorado Springs Health Partners, Pc
Colorado Springs, Colorado, 80907
Express Care Clinical Research
Colorado Springs, Colorado, 80909
Columbia Clinical Research
Columbia, South Carolina, 29201
Rockdale Medical Research
Conyers, Georgia, 30094
Clinical Therapeutics Corp
Coral Gables, Florida, 33134
Bruce Samuels LLC
Covington, Louisiana, 70433
New England Center for Clinical Research
Cranston, Rhode Island, 02920
Z&Z Medical Associates/Internal Medicine Clinical Research
Dallas, Texas, 75235
Cherry Creek Family Practice
Denver, Colorado, 80206
Western Sky Medical Research
El Paso, Texas, 79902
North Georgia Medical Research Institute
Ellijay, Georgia, 30540
Endwell Family Physician
Endwell, New York, 13760
Lillestol Research, LLC
Fargo, North Dakota, 58103
Fleetwood Medical Associates
Fleetwood, Pennsylvania, 19522
Genesys Integrated Group Practice, PC
Flint, Michigan, 48532
Study site
Fort Lauderdale, Florida, 33308
Med Plus South - Strand Family Practice
Garden City, South Carolina, 29576
Horizon Clinical Research Associates, PLLC
Gilbert, Arizona, 85206
Bland Clinic, PA
Greensboro, North Carolina, 27401
Triad Clinical Trials, LLC
Greensboro, North Carolina, 27408
DeGarmo Institute of Medical Research
Greer, South Carolina, 29651
Gulfside Clinical Research
Gulfport, Mississippi, 39501
Desert Endocrinology Clinical Research Center
Henderson, Nevada, 89052
HCA Research
Houston, Texas, 77025
Texas Center for Drug Development, P.A.
Houston, Texas, 77081
American Health Network
Indianapolis, Indiana, 46254
Leading Edge Research, PA
Irving, Texas, 75039
Borgess Heart Institute-Borgess Research Institute
Kalamazoo, Michigan, 49048
Truman Medical Center & Univ Physician Associates
Kansas City, Missouri, 64108
Holston Medical Group
Kingsport, Tennessee, 37660
Gulf Coast Research, LLC
Lafayette, Louisiana, 70508
R/D Clinical Research, Inc.
Lake Jackson, Texas, 77566
Associates Research, Inc
Lansing, Kansas, 66043
Clinical Research Center of NV
Las Vegas, Nevada, 89104
Palm Medical Research Center
Las Vegas, Nevada, 89148
Family Medical Associates
Levittown, Pennsylvania, 19056
Physician Research Collaboration
Lincoln, Nebraska, 68516
Fallbrook Family Health Center
Lincoln, Nebraska, 68521
Medical Investigations, Inc.
Little Rock, Arkansas, 72205
Metro Clinical Research
Littleton, Colorado, 80120
Frederick C. Smith Clinic R & R Research
Marion, Ohio, 43302
Mercy Family Medicine
Mason City, Iowa, 50401
South Texas Institutes of Health
McAllen, Texas, 78501
Vista Medical Research, Inc
Mesa, Arizona, 85206
Clinical Research Advantage
Mesa, Arizona, 85213
Crescent City Clinical Research Center
Metairie, Louisiana, 70006
South Florida Clinical Research Center
Miramar, Florida, 33023
Joslin Diabetes Center
Nashua, New Hampshire, 03063
Hill Country Medical Associates
New Braunfels, Texas, 78130
North Shore Diabetes and Endocrine Associates
New Hyde Park, New York, 11042
Mezitis Education & Research Institute
New York, New York, 10024
Central Sooner Research
Norman, Oklahoma, 73069
Lion Research
Norman, Oklahoma, 73069
North Hills Family Practice
North Richland Hills, Texas, 76180
Complete Family Care
Northglenn, Colorado, 80234
Northport VA Medical Center
Northport, Virginia, 11768
Lucita M. Cruz, M.D., Inc.
Norwalk, California, 90650
Naidu Clinic
Odessa, Texas, 79761
Integris Physicians Services Clinical Research
Oklahoma City, Oklahoma, 73112
Memorial Clinical Research
Oklahoma City, Oklahoma, 73134
Quality Clinical Research
Omaha, Nebraska, 68114
Heartland Clinical Research, Inc.
Omaha, Nebraska, 68134
Ozark Mountains Medical Research
Ozark, Missouri, 65721
Med-Olam Clinical Research
Pasadena, Texas, 77504
Southwest Clinical Research Centers, LLC
Pearland, Texas, 77584
Advanced Clinical Research
Pell City, Alabama, 35128
Pines Research, LLC
Pembroke Pines, Florida, 33028
NISUS Research Northern MI Hospital
Petoskey, Michigan, 49770-2212
Hope Clinical Research
Phoenix, Arizona, 85006
Anasazi Internal Medicine
Phoenix, Arizona, 85032
Tatum Ridge Internal Medicine
Phoenix, Arizona, 85032
Mississippi Medical Research, LLC
Picayune, Mississippi, 39466
Spence Medical Research Center, LLC
Pinckney, Michigan, 39466
Paul W. Davis, MD
Pine Bluff, Arkansas, 71603
Health Science Research Center
Pratt, Kansas, 67124
Private Practice
Raleigh, North Carolina, 27610
Perimeter North Medical Research
Roswell, Georgia, 30076
Crescent Medical Research
Salisbury, North Carolina, 28144
Utah Clinical Trials
Salt Lake City, Utah, 84107
Diabetes & Glandular Disease Clinic , PA
San Antonio, Texas, 78237
California Research Foundation
San Diego, California, 92103
Ritchken and First MDs
San Diego, California, 92117-4961
San Diego Sports Medicine Research and Family Care
San Diego, California, 92120
Crest Clinical Trials
Santa Ana, California, 92701
NuLife Clinical Research, Inc.
Santa Ana, California, 92805
Westside Arthritis and Metabolism Center
Santa Monica, California, 90404
Maine Centers for Endocrinology & Diabetes
Scarborough, Maine, 04074
Summit Reserach Network, LLC
Seattle, Washington, 98104
Jones Family Practice, PA
Shelby, North Carolina, 28150
The Family Doctors
Shreveport, Louisiana, 71115
Diabetes Research Center
South Burlington, Vermont, 05403
Well Pharma Medical Research
South Miami, Florida, 33143
Ozark Medical-Surgical Associates, Ltd.
Springfield, Missouri, 65804
ClinVest Research
Springfield, Missouri, 65807
The Lipid Center
Statesville, North Carolina, 28677
Southwestern Medical Clinic, PC
Stevensville, Michigan, 49127
Dorchester Medical Associates
Summerville, South Carolina, 29485
Madigan Army Medical Center
Tacoma, Washington, 98431
Southeastern Research Associates, Inc.
Taylors, South Carolina, 28687
Shore Health Group
Toms River, New Jersey, 08753
Physicians Research Center
Toms River, New Jersey, 08755
Cotton O'neil Clinic
Topeka, Kansas, 66606
Paradigm Clinical
Tucson, Arizona, 85705
Tucson Clinical Research
Tucson, Arizona, 85712
Community Research Partners, Inc.
Varnville, South Carolina, 29944
Patient's First Health Care
Washington, Missouri, 63090
Holston Medical Group
Weber City, Virginia, 24920
Center for Clinical Trials of San Gabriel
West Covina, California, 91790
Heartland Research Associates, LLC
Wichita, Kansas, 67205
Pharmacotherapy Research Associates, INC
Zanesville, Ohio, 43071
Slovakia7 sites
Diabetologicka ambulancia
Komarnanska, Velky Meder, 932 01
Zeleznicne zdravotnictvo s.r.o., Diabetologicka ambulancia
Košice, 040 01
Diabetologicka ambulancia
Nové Mesto nad Váhom, 915 01
Diabetologicka ambulancia
Prešov
Diabetologicka ambulancia
Šahy, 936 01
Mestska poliklinika Sered, Diabetologicka ambulancia
Sereď, 926 01
Diabetologicka ambulancia
Trebišov, 075 01
Canada6 sites
LMC Endocrinology Centres (Barrie) Ltd.
Barrie, Ontario, L4M 7G1
T.C. Health Center
Carbonear, Newfoundland and Labrador, A1Y 1C4
LMC Endocrinology Centres -(Etobicoke) Ltd. ,
Etobicoke, Ontario, M9R 4E1
G.A. Research Associates Moncton, New Brunswick E1G 1 A7
Moncton, New Brunswick, E1G 1 A7
LMC Endocrinology Centres -(Thornhill)
Thornhill, Ontario, L4J 8L7
LMC Endocrinology Centres (Toronto) Ltd.
Toronto, Ontario, M4R 2G4
India6 sites
Manipal Hospital
Bangalore, 560 017
MV Hospital for Diabetes and Diabetes Research Centre
Chennai, 600 013
Madras Diabetes Research Foundation
Gopālapuram, Chennai, 600 086
Medicity Hospital
Hyderabaad, Hyderabad, 500 036
Diabetes Thyroid Hormone Research Institute Pvt Ltd.
Indore, 452 001
Christian Medical College
Vellore, 632 004
Puerto Rico5 sites
Policlinica Dr. Luis Rodriguez Carrasquillo
Carolina, 00983
Yolanda Sierra Medical Office
Levittown, 00949
Endocrine Lipid Diabetes Research Institute
Ponce, 00717-1471
Centro Clinico San Patricio
San Juan, 00921
Miguel Sosa-Padilla, M.D.
San Juan, 00926
Romania5 sites
CMI Cardiologie
Baia Mare
Paulescu Institute
Bucharest
Anamed SRL
Oradea
Emergency County Hospital Ploiesti
Ploieşti
Policlinica
Timișoara
Malaysia3 sites
Hospital University Kebangsaan Malaysia
Kuala Lumpur, Selangor
University Malaya Medical Centre
Selangor Darul Ehsan, Ehsan
Hospital Putrajaya
Selangor Darul Ehsan, Selangor
Philippines3 sites
Metropolitan Medical Center
Manila
Institute for Studies on Diabetes Foundation
Marikina City
Jose R. Reyes Memorial Medical Center
Sta Cruz, Manila
About this study
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Vildagliptin, Placebo
- Keywords
- Type 2 Diabetes, Vildagliptin
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VildagliptinDrug
VildagliptinDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Vildagliptin Dose 1 | Experimental | Not described Receives: Drug: Vildagliptin |
| Vildagliptin Dose 2 | Experimental | Not described Receives: Drug: Vildagliptin |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.
Measured: 24 weeks
Secondary outcomes (4)
Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM as measured by changes in fasting plasma glucose from baseline to 24 weeks
Measured: 24 weeks
Measure: To evaluate the safety and tolerability of vildagliptin compared to placebo over 24 weeks of treatment as monotherapy in patients with T2DM
Measured: 24 weeks
Measure: To evaluate the long-term safety and tolerability of vildagliptin over the entire study duration as monotherapy in patients with T2DM
Measured: 76 weeks
Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2009 (estimated)
- Study startNov 2008
- Primary completionOct 2010
- Study completionOct 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 338 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00821977
- Sponsor's protocol ID
- CLAF237B2201
- Status last verified
- May 2012
- First submitted
- 13 Jan 2009
- Last updated
- 17 Dec 2020
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT00821977
- Acronym / sponsor ID
- CLAF237B2201
- Conditions
- Diabetes Mellitus, Type 2
- Keywords
- Type 2 Diabetes, Vildagliptin
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 338 participants (actual)
- Lead sponsor
- NovartisIndustry (pharma, biotech, devices)
- Study start
- Nov 2008
- Primary completion
- Oct 2010 (actual)
- Study completion
- Oct 2010 (actual)
- First posted
- 14 Jan 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Vildagliptin Dose 1 | Experimental | Drug: Vildagliptin |
| Vildagliptin Dose 2 | Experimental | Drug: Vildagliptin |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients at least 18 years of age at Visit 1
- Drug naïve patients with T2DM diagnosed at least 2 months prior to Visit 1
- HbA1c ≥ 7.0 % and ≤ 10.0% at Visit 1
- Body Mass Index (BMI) in the range of 22-45 kg/m2 at Visit 1
Key exclusion criteria (3 listed)
- Pregnant or lactating female
- FPG ≥ 270 mg/dL (≥15 mmol/L)
- Other protocol-defined inclusion/exclusion criteria may apply
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vildagliptin | Drug | Vildagliptin Dose 1 |
| Vildagliptin | Drug | Vildagliptin Dose 2 |
| Placebo | Drug | Placebo |
Primary outcome
Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks.
Time frame: 24 weeks
4 secondary outcomes
Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM as measured by changes in fasting plasma glucose from baseline to 24 weeks
Time frame: 24 weeks
Measure: To evaluate the safety and tolerability of vildagliptin compared to placebo over 24 weeks of treatment as monotherapy in patients with T2DM
Time frame: 24 weeks
Measure: To evaluate the long-term safety and tolerability of vildagliptin over the entire study duration as monotherapy in patients with T2DM
Time frame: 76 weeks
Measure: To evaluate the body weight change from baseline with vildagliptin compared to placebo after 24 weeks of treatment as monotherapy in patients with T2DM
Time frame: 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2020.
- Results for CLAF237B2201 from the Novartis Clinical Trials websiteLink provided by the sponsor.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
176 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Vildagliptin in people with Diabetes Mellitus, Type 2, run by Novartis at 176 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 176 sites in United States, Slovakia, Canada, India, Puerto Rico and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure: To evaluate the efficacy of vildagliptin as monotherapy in patients with T2DM by assessing changes in HbA1c from baseline to 24 weeks. (time frame: 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2020.